E
ASCO 2016 Posters 2

The changing face of the SCCHN landscape

A example of how different targeted therapy and immunotherapy combinations could be both useful and different from what we've seen before

July 12, 2016
E
No Cycling

JUNO setback by Patient Deaths due to CAR T Cell Neurotoxicity

Juno ROCKET trial put on clinical hold following 3 death due to cerebral edema. What's the skinny?

July 7, 2016
E
ASCO 2016 Posters 6

Can epigenetics play a role in immunomodulation?

Will priming the tumour microenvironment with epigenetic therapies such as HDACs lead to enhanced activity with subsequent immunotherapy?

July 7, 2016
E
ASCO 2016 Posters 3

One Step Beyond

With so many new anti-cancer agents, including immunotherapies, emerging in company pipelines, this means that we could see the evolution of important therapy sequences... going beyond combinations.

July 5, 2016
E
Beach Huts

Xencor and Novartis storm the hematologic bispecific market

The oncology bispecific market is heating up with J&J collaborating with Macrogenics and Novartis with Xencor. We discuss the skinny...

June 28, 2016
E

The potential downside of cancer immunotherapy

We've seen some wonderful responses with checkpoint blockade and cancer immunotherapies, but there are some downsides that need to be considered.

June 27, 2016
E
Dr Johanna Bendell ASCO 2016

How to turn a cold tumour into a hot one

Can we turn a cold tumour into a hot one where some patients can respond to therapy?

June 23, 2016
E
ASCO 2016 Collective Wisdom

Checkpoint blockade in MSI High cancers

Update on ASCO checkpoint blockade data for colorectal and other MSI-High cancers

June 22, 2016
E
IMG_6454

Immunoscore validated as an important biomarker for colon cancer

An easy to use new biomarker emerges to help oncologists select colon cancer patients for cancer immunotherapies.

June 20, 2016
E
T-cells attacking a cancer cell. Digital illustration.

Reader Mailbag – TCR T cell Gene Editing in Multiple Myeloma

Gene editing is coming to the US CAR T cell space - what's happening and what will the impact be?

June 17, 2016
E
Wall of People at ASCO 2016

Beyond PD-L1 Immunotherapy Biomarkers

Can we find and use several biomarkers to triangulate responders and non-responders?

June 16, 2016
E
Chicago John Hancock Center View

Urothelial Cancer Immunotherapy is a Competitive Landscape

A look at the increasingly competitive metastatic urothelial carcinoma landscape

June 15, 2016
E
Morgan Grafitti Wall

Contemplations on ASCO Lung Cancer Data with Dr Stephen Liu

What to make of the various combination trials presented at ASCO 2016?

June 13, 2016
E
ASCO16 Chicago 5

5 Important and Emerging Trends from ASCO 2016

A number of points of strategic importance fell out of the ASCO data dump. What are they and why do they matter?

June 9, 2016
E
ASCO16 Chicago 6

ASCO 2016 Monday Blog #ASCO16

Commentary from Monday at ASCO 2016 American Society of Clinical Oncology annual meeting in Chicago

June 6, 2016
E
ASCO 2016 Annual Meeting

BMS Ipilimumab prostate cancer immunotherapy trial fails but where is the data?

When Big Pharma turns into Bad Pharma...

June 5, 2016
E
View from ASCO annual meeting

ASCO 2016 Sunday Blog #ASCO16

Top-line commentary from Sunday at ASCO 2016 annual meeting.

June 5, 2016
E
Chicago River

ASCO 2016 Chicago Saturday Blog #ASCO16

Top-line commentary from Saturday at ASCO 2016 annual meeting.

June 4, 2016
E
Dr Tom Dubensky AACR

What we learnt at AACR about Aduro ADU-S100

Can we safely combine a STING agonist with a checkpoint inhibitor to generate more effectiveness in melanoma and lymphomas? We asked experts at AACR what they really thought...

May 25, 2016
E
New Orleans Voodoo

Statistical Challenges of Immunotherapy Clinical Trial Design

What can we learn about clinical trial design from immunotherapy combinations?

May 23, 2016
E
Miami Beach

Drug Discovery Targets Cancer Vulnerabilities

Commentary from the AACR Precision Medicine Conference in Miami on Targeting the Vulnerabilities of Cancer.

May 20, 2016
E
New Orleans Calle Real Street

George Coukos Drives Novel Ovarian Cancer Immunotherapies Forward

How can we improve T cell trafficking in ovarian cancer? Professor Coukos highlights numerous ways this could be achieved!

May 16, 2016
E
Nawlins Street

Is APRIL an exciting new target in Multiple Myeloma?

A look at the BCMA/APRIL landscape in multiple myeloma - this is rapidly becoming a competitive target

May 11, 2016
E
New Orleans American Queen

Targeting OX40 in advanced cancers – Part 2

Beyond checkpoint blockade, companies are now exploring what happens when you combine them with immune agonists such as OX40. Here we explore an industry perspective.

May 10, 2016
E
Dr Bernard Fox at #AACR16

AACR Cancer Immunotherapy Insights from Dr Bernard Fox

A wide ranging discussion about how to light the fires in non-immunogenic or cold tumours - OX40, STING, vaccines and more discussed!

May 9, 2016
E
Driving St Charles Streetcar

Can chemotherapy improve checkpoint blockade in advanced colorectal cancer?

Can we safely and effectively add a checkpoint inhibitor to standard chemotherapy and VEGF inhibition? Early proof of concept in patients with metastatic colorectal cancer.

May 4, 2016
E
Dr Michel Sadelain AACR

Breaking the Immunology Rules – an interview with Dr Michel Sadelain on how CAR T cell therapy will crack solid tumors

At the recent AACR meeting, Dr Michel Sadelain gave a presentation on turbocharged CAR T cells, and shared some of his ideas on how to move the field forward.

May 5, 2016
E
St Charles Streetcar New Orleans

Controversy: Is Chemotherapy Immunotherapy?

Chemotherapy can have a potentiating effect on cancer immunotherapy. The positive effects may surprise some readers...

May 3, 2016
E
Claws

7 Significant Things I Learned at AACR16 That You Don’t Want to Ignore

What were the major learning points from AACR that will make an impact over the next 1-2 years? Chhhhanges are afoot...

May 2, 2016
E
Dan Chen and Ira Mellman on Novel Targets Podcast

Thunderbirds are GO!

Season 2 of the Novel Targets has launched, plus the eagerly awaited April Readers Q&A Mailbag

April 29, 2016
E
AACR 2016 Posters

AACR 2016 New Orleans Day 4 Blog

Commentary on Tuesday sessions at AACR 2016 annual meeting

April 19, 2016
E
AACR16 Registration

AACR 2016 New Orleans Day 3 Blog

Commentary on Monday at AACR 2016 annual meeting

April 18, 2016
E
New Orleans AACR 2016

AACR 2016 New Orleans Day 2 Blog

Commentary from Sunday at 2016 AACR annual meeting

April 17, 2016
E
New Orleans StreetCar

AACR 2016 New Orleans Day 1 Blog

Commentary on Day 1 of AACR 2016 annual meeting in New Orleans.

April 16, 2016
E
European Cafe

Osimertinib front-line data wows European Lung 2016

First-line data for AstraZeneca’s ($AZN) third generation EGFR inhibitor osimertinib (Tagrisso) impresses at the 2016 European Lung Cancer Conference in Geneva.

April 14, 2016
E
Dawlish Trainspotting

AACR 2016 CD40 Cancer Immunotherapy

In this preview of AACR 2016, we're looking at the CD40 landscape, some of the new companies that have entered the scene and what presentations to look out for at AACR 2016 (and why they matter).

April 8, 2016
E
British Javelin Train

OX40 immune agonists at AACR 2016

Today post is on OX40 (CD134) as a novel immuno-target and what the OX40 cancer immunotherapy landscape looks like.

April 7, 2016
E
Macarons in shop window

AACR 2016 GITR Cancer Immunotherapy

There are now several agonist antibodies in development and entering the clinic that seek to activate GITR, and new data is expected at AACR 2016.

April 6, 2016
E
St Charles Streetcar New Orleans

AACR 2016 Cancer Immunotherapy Targeting IDO1 TDO

This post looks at some of the data at AACR 2016 for cancer immunotherapies that target IDO1 and TDO and their downstream effectors.

April 5, 2016
E
Iwakuni Bridge Cherry Blossoms

AACR 2016 A Preview of anti TIM-3 and LAG-3 Checkpoints

A look at alternative checkpoint inhibitors, anti-TIM-3 and LAG-3 compounds in early development at AACR

April 1, 2016
E
Washington DC Cherry Blossoms

Beyond Blinatumomab – Update on Bispecific T cell Engagers

In this post I've taken a close look at one cancer immunotherapy approach with a lot of data at AACR - bispecific T cell engagers.

March 31, 2016
E
Port Sunglight Spring

Future of Cancer Immunotherapy

Commentary on some of the latest cancer immunotherapy papers

March 29, 2016
E
New Orleans Jazz

Top 10 Abstracts at AACR 2016

Pick of 10 abstracts at AACR 2016 annual meeting in New Orleans that may answer critical cancer research questions

March 17, 2016
E
New Orleans riverfront streetcar

What’s Hot at AACR 2016? Annual Meeting Preview 1

Cancer Immunotherapy dominates AACR 2016 annual meeting in New Orleans.

March 16, 2016
E
Amsterdam Centraal Station

Gems from the EBCC10 Poster Hall

Review of 4 noteworthy posters at the 2016 European Breast Cancer Conference in Amsterdam organised by European Cancer Organisation ECCO

March 10, 2016
E
Koko Crater Botanical Garden

Trends in Haplo transplants impact Bellicum

Trends in Haplo stem cell transplants may impact Bellicum Pharmaceuticals adjunct T Cell therapy BPX–501

March 9, 2016
E
Chinatown Honolulu

Is TIM–3 the next important checkpoint target?

Could immune resistance be reversed or prevented by the addition of appropriate checkpoint blockade? Which ones matter though, that is the critical question?

March 3, 2016
E
King Kamehameha Statute Honolulu

Could a Novel Cell Therapy replace CAR T Cell Therapy?

Interview at BMT Tandem 2016 about a novel cell therapy that could compete with or replace CAR T cell therapy

March 1, 2016
E
View of Lanikai Beach Oahu

Are checkpoints playing with fire?

Commentary on presentation by Dr Philippe Armand at BMT Tandem meeting on “Checkpoint Blockade in SCT, Data & Hope, Promise & Peril”

February 25, 2016
E
Makapuu Beach Hawaii

Optimizing CD19 CAR T Cell Therapy

Interview with Dr Michael Jensen on CD19 CAR T Cell Therapy

February 23, 2016
E
Hawaii Pineapples

Challenges and Opportunities of CAR T Cell Therapy in CLL

Interview at BMT Tandem 2016 with Dr David Porter U Penn on CD19 targeted CAR T cell therapy in CLL

February 19, 2016
E
North Shore Surf Shop

What’s hot at BMT Tandem 2016 in Honolulu?

Preview of noteworthy sessions at 2016 BMT Tandem meeting in Honolulu, Hawaii

February 17, 2016
E
View from Diamond Head HI

What’s driving the GvHD Landscape? #BMTTandem16

What are some of the strategic trends and drivers in the Graft versus Host Disease (GvHD) space at #BMTTandem16?

February 9, 2016
E
Unum C suite

Will Unum’s approach take the CAR T cell therapy market by storm?

Unum have developed a completely different approach to traditional CAR T cell therapies. Will they make an impact in patients?

February 4, 2016
E
Dr Ann Leen ASH15

Immunotherapy for Lymphoma using T cells Targeting Multiple Tumor-Associated Antigens

A novel cell therapy approach uses T cells targeting multiple tumor-associated antigens.

February 3, 2016
E
San Francisco Hercules

Update on Targeted therapies and Immunotherapies in Gastric Cancer

Who will move the needle in gastric and oesophageal cancers - targeted therapies or checkpoint immunoherapies?

January 27, 2016
E
Franciscan Crab Restaurant San Francisco

Will pembrolizumab extend its activity in GI cancers?

Will checkpoint blockade be effective in multiple GI cancers and if so, why?

January 25, 2016
E
Streets of San Francisco

Why didn’t Ipilimumab plus Chemo work in Metastatic Urothelial Cancer?

A trial of gemcitabine plus cisplatin plus ipilimumab in patients with metastatic urothelial cancer failed to meet it's primary endpoint.

January 22, 2016
E
San Francisco JPM16 Day 3

Day 3 Highlights from JP Morgan Healthcare Conference #JPM16

Commentary on Wednesday corporate presentations at 2016 JP Morgan Healthcare conference in San Francisco

January 13, 2016
E
San Francisco JPM16 Day 2

Highlights of #JPM16 Healthcare Conference Day 2

Commentary on some of the presentations at Day 2 of JP Morgan Healthcare conference in San Francisco.

January 12, 2016
E
San Francisco JPM16 Day 1

Highlights of #JPM16 Healthcare Conference Day 1

Commentary around some of the corporate presentations at Day 1 of the 2016 JP Morgan Healthcare conference in San Francisco.

January 11, 2016
E
ASH Exhibit Hall

New Horizons in CLL Treatment

ASH 2015 interview with Dr Ian Flinn, Director of the Blood Cancer Research Program at the Sarah Cannon Research Institute.

January 5, 2016
E
Prof Qasim ASH 2015 poster

Understanding the Cellectis UCART19 Case Report – Part 2 of an Interview with Prof Waseem Qasim

Part 2 of ASH 2015 interview with Prof Waseem Qasim (GOSH) on the first in man gene edited allogeneic CAR T cell therapy.

December 16, 2015
E
Prof Qasim UCART19 ASH 2015 Poster

Potential of Gene Editing – Part 1 of Interview with Prof Waseem Qasim

Part 1 of an interview with Prof Waseem Qasim.

December 15, 2015
E
SABCS 2014 San Antonio Riverwalk

Checkpoint therapy update in metastatic breast cancer

Adding chemotherapy or an ADC boosts the immunogenic effects prior to checkpoint therapy in metastatic breast cancers

December 11, 2015
E
ASH 2015 Hematology Orlando

Highlights from Plenary Sunday at #ASH15

Commentary on Plenary Sunday at the 2015 ASH annual meeting in Orlando.

December 6, 2015
E
ASH 2015 Orlando

Highlights from Saturday at ASH 2015 Annual Meeting #ASH15

Commentary on Saturday at ASH15

December 5, 2015
E
SITC 2015 Biomarker Debate

Future of Cancer Immunotherapy Biomarkers

Where is the field of immune biomarkers going beyond PD-L1 in the next few years?

November 27, 2015
E
European Cafe

ASH15 Preview Checkpoints in classical Hodgkin Lymphoma

Checkpoints in classical Hodgkins Lymphoma - how is the data holding up one year on?

November 25, 2015
E
Dr Chris Heery NCI

Exploring the Potential of Therapeutic Cancer Vaccines

At the recent Society for Immunotherapy of Cancer (SITC) annual meeting, Dr Chris Heery presented a poster on the results of a phase 1 clinical trial to evaluate the safety and tolerability of a therapeutic vaccine targeting brachyury.

November 23, 2015
E
SITC 2015 Land Grab

Q&A on hot topics in CAR T cell therapies

Our latest Q&A based on reader questions - In the Hot Spot: On CAR T cell therapies

November 18, 2015
E
GRACE Immunotherapy Patient Forum SITC

Novel Immunotherapies and Combinations

Interview with Dr Mario Sznol on Novel Immunotherapies and Combinations

November 17, 2015
E
Tom Gajewski SITC 2015

Gut Bacteria Impact Checkpoint Inhibitor efficacy

Dr Tom Gajewski (University of Chicago) talks about work from his lab that shows the gut microbiota can impact the efficacy of checkpoint inhibitors.

November 16, 2015
E
Millefeuille Pastry

Strategies to overcome CAR T cell therapy resistance

Interview with a leading expert on strategies to overcome CAR T Cell Therapy Resistance

November 12, 2015
E
National Harbor Maryland

How long do we need to give a checkpoint inhibitor for?

At SITC 2015, we heard a tremendous amount of data, but a fresh controversy emerged regarding checkpoint inhibition...

November 11, 2015
E
Crab Cakes Maryland

Do Cellectis CAR T Cells Really Work?

Expert opinion on First Clinical Application of TALEN Engineered Universal CAR19 T Cells in B-ALL

November 10, 2015
E
Fall Colors National Harbor MD

Mixed results with Macrogenics enoblituzumab at SITC

Enoblituzumab is an immune stimulant that targets B7-H3 leading to more T cells.

November 7, 2015
E
National Harbor Maryland

Did the epacadostat combo data disappoint at SITC?

Is Incyte's epacadostat (IDO1 inhibitor) ready for prime time?

November 7, 2015
E
SITC 2015 National Harbor Gaylord MD

SITC 2015 – what did we learn from the cancer immunotherapy workshops?

Review of the highlights from the SITC 2015 pre-meeting workshops

November 5, 2015
E
Downtown Disney Orlando

What IS Hot at ASH 2015 in Orlando? #ASH15 abstracts – Preview 1

Most of the abstracts for the 2015 annual meeting of the American Society of Hematology (ASH) have just gone online. This is a quick initial preview of a few that caught my attention in the immunotherapy space.

November 5, 2015
E
SITC 2015 National Harbor View

SITC 2015 International Cancer Immunotherapy Symposium

Commentary on the International Cancer Immunotherapy Symposium held at SITC 2015

November 4, 2015
E
SITC 2015 Cancer Immunotherapy

Preview of SITC 2015 Cancer Immunotherapy Meeting

Preview of what's hot at the 2015 Society for Immunotherapy of Cancer (SITC) annual meeting at National Harbor, MD.

November 3, 2015
E
Wiener Wisenrad

CD40 as a Cancer Immunotherapy Target

Companies in the ImmunoOncology space are looking at ways to improve responses with checkpoint inhibitors. Adding an immune agonist is one way to do this.

November 3, 2015
E
Vienna Wiesenrad Gorilla Amusement

How do we boost the effectiveness of checkpoint inhibitors?

A primer on immunocytokines in cancer immunotherapy with a focus on Roche's CEA-IL2v as a example.

November 2, 2015
E
Dr Jerome Galon ECC2015 Vienna

Immunosurveillance, Immunoscore & Personalized Cancer Immunotherapy – an interview with Jérôme Galon

Interview with Dr Jérôme Galon on Immunosurveillance, Immunoscore and Personalized Cancer Immunotherapy.

October 30, 2015
E
Fall Colors Boston

What’s Hot at AACR #Targets15 in Boston?

Preview of the key topics coming up at the AACR-NCI-EORTC Molecular Targets meeting in Boston, including Pasi Janne's interesting data on T790M negative NSCLC...

October 27, 2015
E
Austrian Traditional Costume

Controversies in lung cancer immunotherapy

Should we be using the PDL1 antibody assay to screen patients for therapy with anti-PD1 and PD-L1 checkpoint inhibitors or? How useful is the test? The debate is heating up!

October 26, 2015
E
ECC Go the Extra Mile Shoe

Why combine radiation with cancer immunotherapy?

Radiation has the potential to generate an immune response that may lead to an abscopal effect when combined with a checkpoint inhibitor.

October 21, 2015
E
Cambridge River Cam

Is Combining a Checkpoint plus an EGFR inhibitor a risky combination?

Will an increase in ILD cases scupper the AZD9291 plus durvalumab combination study in lung cancer? Will there be an advantage for Clovis or not?

October 13, 2015
E
ECC 2015 Go the Extra Mile

Where are the breakthroughs coming in Soft Tissue Sarcoma?

Interview at ECC 2015 with Dr George Demetri on new developments in Soft Tissue Sarcoma

October 6, 2015
E
Dr Nora Disis ECC 2015

Potential of Checkpoint Inhibitors in Ovarian Cancer

Interview with Dr Nora Disis about the phase 1b trial results for avelumab in ovarian cancer and the challenges of developing these agents in non-hypermutated tumour types

October 5, 2015
E
ECC Vienna Highlights Day 3

What’s hot at Day 3 of European Cancer Congress?

Commentary on Day 3 of the European Cancer Congress in Vienna

September 28, 2015
E
European Cancer Congress Vienna

ECC Day 2 Highlights – Checkpoints in Lung and Bladder Cancer

Commentary on Day 2 of the European Cancer Congress in Vienna

September 27, 2015
E
ECC 2015 Press Conference

ECC Day 1 Highlights – the battle for Advanced Renal Cell Carcinoma

Highlights from Day 1 of the ECC 2015 (ECCO) meeting in Vienna

September 25, 2015
E
Vienna Torte

Novel Targets Podcast 6 – Immune Agonists

What happens when we literally step on the gas with immune agonists?

September 24, 2015
E
Paignton Dartmouth Steam Railway

Checkpoint inhibition: targeting TIM-3

T cell immunoglobulin and mucin domain-containing molecule-3 (TIM-3) is widely expressed on immune cells. What's the potential for a TIM-3 checkpoint inhibitor?

September 17, 2015
E
New York Waterfront Photo

What’s hot at the AACR International Cancer Immunotherapy Conference?

Review of noteworthy abstracts at CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference in New York

September 16, 2015
E
Dr Holbrook Kohrt

Holbrook Kohrt leads the way in Targeting CD137

Holbrook Kohrt is a Stanford medical oncologist and clinical researcher who is leading the way in cancer immunotherapy combination strategies targeting CD137 (4-1BB).

September 15, 2015
E
Immunocore Milton Park Oxford

Immunocore ImmTAC TCR platform offers combination promise

Immunocore is an immuno-oncology company with an innovative approach to targeting T Cell Receptors (TCR) using their proprietary ImmTAC (Immune mobilising monoclonal TCRs against cancer) technology platform.

September 14, 2015
E
Vienna Ferris Wheel

ECC Vienna Preview 2 Oral Presentations

What's hot at ECCO 2015 in the oral sessions? An in-depth preview of what we can expect to hear about in Vienna...

September 10, 2015
E
Vienna Coffee House

ECC Vienna Preview 1 Late Breaking Abstracts

What's hot in the 2015 ECCO late breaking abstracts in Vienna? Find out here...

September 8, 2015
E
St Bartholomews Hospital Barts London

Atezolizumab PDL1 Checkpoint Inhibitor will change Bladder Cancer Treatment

Atezolizumab is expected to change the standard of care for the treatment of metastatic urothelial bladder cancer

September 3, 2015
E
Philadelphia Suburban Station

Adoptive Cell Therapies – an interview with Dr Carl June

Dr Carl June on progress of CAR T cell therapies in CLL, myeloma and solid tumours

August 14, 2015
E
Nawlins

Adoptive Cell Therapy: An Interview with Dr Steven Rosenberg

We know that TILs can be effective in advanced melanoma, but what about common epithelial solid tumours? Can it work in these cancers too? Find out from Dr Rosenberg's latest work what's happening...

August 12, 2015
E
English Roses

Oncolytic viruses – are they ready for prime time?

Oncolytic viruses are fast becoming a hot new area in cancer research but who are the players and where is this field going?

August 6, 2015
E
Kensington Gardens London

Will targeting NY-ESO-1 prime the immune system in cancer?

Exploring NY-ESO-1 as a valid target in sarcoma, multiple myeloma and metastatic melanoma...

August 3, 2015
E
Cambridge Clare College Bicycles

BMS and Exelixis announce new renal cell cancer data

Will checkpoint inhibitors make their mark in renal cell carcinoma and how will they be integrated into a treatment paradigm dominated by VEGF inhibitors?

July 22, 2015
E
Margate

Novel Targets Podcast: Non-inflamed Tumours

Can we find new ways to target prostate cancer and other non-immunogenic tumours with immunotherapies? The answer may surprise...

July 21, 2015
E
Cambridge Punting

AstraZeneca take a punt on immuno-oncology

Interview with Dr Rob Iannone of AstraZeneca on their IO pipeline

July 15, 2015
E
Dr William Pao Roche

Do you need a CAR T Cell Therapy to be a Global Cancer Immunotherapy Company?

Interview with Dr William Pao on the Roche antibody based cancer immunotherapy strategy.

July 1, 2015
E
Juno CELG collaboration

Juno and Celgene’s unexpected CAR-T cell and TCR collaboration

Editas presented some elegant work using their gene editing technology with CRISPR/Cas9 to modify T cells at ASGCT. Who would have guessed a short time afterwards Juno and Celgene would sign a 10 year collaboration?

June 30, 2015
E
Dr James Gulley ASCO 2015

Future of Prostate Cancer Immunotherapy

ASCO 2015 interview with Dr James Gulley from NCI on Prostate Cancer Immunotherapy.

June 29, 2015
E
Chicago Riverwalk

Checkpoint inhibitors show early promise in Small Cell Lung Cancer

We've heard a lot about checkpoint immunotherapies in non-small cell lung cancer (NSCLC), but what about it's deadlier cousin, small cell lung cancer (SCLC)? Find out more...

June 16, 2015
E
Chicago Riverwalk

Beyond the Big Four in checkpoint blockade

Beyond the Big Four in checkpoint inhibitors, there is a raft of other companies anxious to get in the action. We take a look at Merck Serono and their progress with avelumab, an anti-PDL1 antibody

June 11, 2015
E
Chicago Trains

Combined checkpoint inhibition and chemotherapy – useful or not?

How do we help patients who are non-responders or have stable disease respond to checkpoint inhibitors? Will chemotherapy combos help or not?

June 8, 2015
E
Dr Jedd Wolchok ASCO 2015

Highlights of Day 4 at ASCO 2015 Annual Meeting

Highlights from Monday at the 2015 ASCO annual meeting in Chicago

June 1, 2015
E
ASCO 2015 Day 3 Live Blog

ASCO 2015 Highlights of Day 3

What's hot on Plenary Sunday at ASCO 2015? We'll be updating this blog post during the day.

May 31, 2015
E
ASCO 2015 Day 2 Live Blog

Highlights of ASCO 2015 Day 2 Live Blog

Highlights from Day 2 at ASCO 15 in Chicago

May 30, 2015
E
ASCO 2015 Day 1 Highlights

ASCO 2015 Cancer Immunotherapy – Reflections on Day 1

Reflections on data presented in the first cancer immunotherapy press briefing at ASCO 2015

May 30, 2015
E
Pralines

Suicide Genes – what are they and are they really needed?

Do you need to incorporate a suicide suicide switch into CAR T cells that allows you to turn off the response, force the T cells to self-destruct?

May 28, 2015
E
New Orleans American Queen

New therapies for multiple myeloma may make an impact

Data at ASGCT and ASCO highlight potential new treatments in development for multiple myeloma

May 18, 2015
E
Gumbo Shop New Orleans

AUA 2015 Update on bladder cancer

Update on checkpoint inhibitors in urothelial bladder cancer from AUA 2015 and what's in store for new developments with this disease.

May 15, 2015
E
Chicago River ASCO

Highlights of ASCO15 Abstracts – Preview No 1

First in a series of previews of ASCO 2015 annual meeting abstracts.

May 13, 2015
E
Dr Tom Gajewski (Chicago)

Tom Gajewski takes the STING out of Cancer

Dr Tom Gajewski is working on STING agonists that may have a major role to play in cancer immunotherapy.

May 13, 2015
E
New Orleans Cafe Du Monde

Promise of Cancer Immunotherapy highlighted at Immunology 2015

At the 2015 annual meeting of the American Association of Immunologists (AAI) in New Orleans, leading experts shared their insights on the “Promise of Cancer Immunotherapy."

May 11, 2015
E
Chicago L Train

Top 10 immunotherapy studies with checkpoint blockade at ASCO 2015

What are the hot checkpoint studies to watch out for at ASCO 2015? We created a cheat sheet to follow and track the data as tsunami hits...

May 8, 2015
E
AACR 2015 Audience

What happens when you combine checkpoint blockade with an immune stimulant in cancer?

What happens when we combine a checkpoint with an immune stimulant in advanced melanoma?

May 6, 2015
E
Reading Market Food

AACR Gems from the Poster Halls in ImmunoOncology

Beyond monotherapy with checkpoint inhibition, what combinations or sequences might be useful to explore next?

April 28, 2015
E
AACR 2015 Checkpoint Inhibitor Posters

Where are checkpoint inhibitors going next?

Beyond lung cancer and melanoma, what other tumour types represent the low hanging fruit for checkpoint monotherapy?

April 24, 2015
E
AACR 2015 Annual Meeting Philadelphia

Is this the end of ipilimumab in melanoma?

As the anti-PD-1 blockers show superiority in front-line metastatic melanoma, is this the end for Yervoy?

April 23, 2015
E
AACR 2015 MPDL3280A TNBC

Top 10 Highlights of AACR 2015

The annual meeting of the American Association for Cancer Research ended today. Find out what were our top 10 highlights.

April 22, 2015
E
Philadelphia Suburban Station

Checkpoint Inhibitor Data Rocks AACR 2015

Checkpoint Inhibitor data is a hot topic at AACR 2015. Data showed they may work in TNBC and also two checkpoints are better than one.

April 21, 2015
E
Reading Terminal Market Philadelphia

Reflections on AACR 2015 Cancer Immunotherapy Data

Cancer Immunotherapy is one of the hot topics at the 2015 AACR annual meeting in Philadelphia.

April 20, 2015
E
City of London Griffin

Anti-CTLA4 blockade with ipilimumab may be effective in hematologic malignancies

Does checkpoint blockade with CTLA4 have a role to play in hematologic malignancies?

April 15, 2015
E
UCL London Warren Street

UCL Drives CD19 CAR T Cell Therapy Forward in Europe

University College London (UCL) is leading the way in European clinical trials of CAR T Cell therapies that target CD19.

April 14, 2015
E
Bridgewater Canal Salford

Novel Combination Approaches with Checkpoint Inhibitors

Emerging data on different combinations with checkpoint inhibitors suggests that this may increase response rates and outcomes for cancer patients. Find out more...

March 31, 2015
E
Novartis Cambridge MA

What is STING and why does it matter in cancer immunotherapy?

Novartis have announced a deal with Aduro Biotech for access to their STING-targeted CDN platform technology.

March 30, 2015
E
Paris La Madeleine

How do we improve responses to checkpoint inhibitors in lung cancer?

The mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

March 26, 2015
E
Olives

Will CAR-T cells make an impact in solid tumours?

Novel targets are emerging in urothelial bladder cancer which may offer new therapeutic options for antibody and CAR-T cell therapy development.

March 25, 2015
E
Madrid Pescaderia

What would Charles Darwin make of renal cell carcinoma?

Why is renal cell carcinoma so challenging from a clinical and sequencing perspective?

March 23, 2015
E
WTC Memorial Liberty State Park

Cellular therapy with EBV-CTL reduces death post stem cell transplant

What is the potential of a new cell therapy with cytotoxic T lymphocytes against Epstein Barr Virus (EBV-CTL)?

March 20, 2015
E
Philadelphia Skyline

Emerging new biomarker for predicting checkpoint inhibitor responders

Predictive biomarkers of response will be key to reimbursement of immunotherapies in Europe. One is potentially emerging for ipilimumab (Yervoy), which may be useful in speeding up access.

March 19, 2015
E
Love Philadelphia

AACR 2015 Cancer Immunotherapy Preview

What are the emerging new trends in cancer immunotherapy? Beyond monotherapy lies many combination opportunities yet to be explored. At AACR in April, we will see a raft of novel approaches being discussed.

March 11, 2015
E
ASH14 CHECKPOINTS

How to enhance checkpoint inhibitors in hematologic malignancies

Will checkpoint inhibitors make an impact in hematologic malignancies or will novel combinations be needed?

March 4, 2015
E
ASCO GU Orlando

How to make non-immunogenic cancers sensitive to checkpoint inhibitors

Not all cancers respond to checkpoint inhibitors - how can we change that situation? Here's one example, using prostate cancer as a model...

March 2, 2015
E
Dr Krishna Komanduri University of Miami

CAR-T and Gene Therapy excite BMT Tandem Meeting

Dr Krishna Komanduri discusses some of the best abstracts at the 2015 BMT Tandem meeting in San Diego.

February 25, 2015
E
London Coffee Stand

CAR-T Cell Therapies from China are a Competitive Threat

Cellular Biomedicine Group (NASDAQ: CBMG) has acquired rights to the Chimeric Antigen Receptor T cell (CAR-T) therapy of the PLA General Hospital in Beijing.

February 11, 2015
E
P1030552

The application of TILs, CARs and TCRs in cancer research

What does the evolving landscape for CAR, TIL and TCR cell therapies look like?

February 10, 2015
E
Rosenberg ASH Featured Image

Tumour infiltrating lymphocytes TILs: what are they and why do they matter?

The NCI have been at the forefront of developing novel cancer immunotherapies for several decades, but what is the current status of their groundbreaking work? Find out more in this primer on TILs.

February 5, 2015
E
Iron Men of Crosby

Bellicum moves BPX-501 T Cell Therapy forward $BLCM

What's the vision for Bellicum Pharmaceuticals? In an in-depth interview CEO Tom Farrell and COO Annemarie Moseley discuss the benefits offered by their new products in development.

January 13, 2015
E
Genetech Drug Development with Gene Antibody

Next generation approaches to immuno-oncology – where next?

What's next in immuno-oncology: what are potential ways to tackle the patients who do not respond to checkpoint immunotherapy?

January 8, 2015
E
Dr Julianne Smith Cellectis

Cellectis ramps up CAR-T development in 2015

What makes the Cellectis Chimeric Antigen Receptor CAR-T cell therapy different and what are the milestones expected in 2015?

January 6, 2015
E
ASH 2014 GvHD Plenary Dr Wei Li

Targeting the unmet medical need in GvHD

Graft versus Host disease (GvHD) is an area of tremendous unmet medical need that is triggering the interest of a number of biotech and rare disease companies.

January 5, 2015
E
SABCS 2014 San Antonio Riverwalk

Do Checkpoint Inhibitors work in Triple Negative Breast Cancer?

There is a lot of interest in checkpoint inhibitors, do they look they will be effective in Triple Negative Breast Cancer?

December 10, 2014
E
Dungeness Crab San Francisco

ASH 2014 Day 3 Live blog #ASH14

"Manic Monday" at the annual meeting of the American Society of Hematology features multiple oral sessions run at the same time!

December 8, 2014
E
San Francisco Festive Cable Car

ASH 2014 Day 2 Live Blog #ASH14

Coverage of Day 2 of the annual meeting of the American Society of Hematology in San Francisco.

December 7, 2014
E
Historic Trolley Car San Francisco

ASH 2014 Day 1 Live Blog #ASH14

It's Day 1 of the 2014 annual meeting of the American Society of Hematology meeting in San Francisco.

December 6, 2014
E
San Francisco Coit Tower

ASH 2014 Annual Meeting Multiple Myeloma Preview

ASH 2014 Multiple Myeloma data looks like it offers much promise for new treatments as well as an increasingly competitive marketplace

December 2, 2014
E
Nature Letter PDL1 Roy Herbst

The Science of PD1 PDL1 Cancer Immunotherapy

The science of targeting PD-1 and it's ligand PD-L1 in cancer immunotherapy is highlighted in five Letters published in Nature this week.

November 26, 2014
E
Hy Levitsky Roche SITC 2014

Targeting CD40 in Cancer Immunotherapy

How can we jumpstart the immune system to enable more patients to respond? At SITC we learned more about targeting CD40 to achieve this.

November 20, 2014
E
Fall Colors National Harbor MD

Can you reduce Graft versus Host Disease GvHD by regulating gut bacteria?

At the SITC 2014 annual meeting, Dr van den Brink presented data on how the bacteria in our gut (the intestinal microbiome) can impact GvHD.

November 18, 2014
E
SITC 2014 Entrance

Challenge of Cytokine Release Syndrome in CD19 CAR-T Cell Therapy

At the Society for Immunotherapy of Cancer (SITC) meeting last week, one of the Hot Topic sessions that took place after the conference formally ended was in managing the toxicities associated with chimeric antigen receptor T cell (CAR-T) therapy.

November 17, 2014
E
SITC 2014 Oral Poster Session

Will combining anti-OX40 with a checkpoint inhibitor matter in cancer?

OX40 could be an exciting new target in immune-oncology that could be combined with checkpoint inhibitors to improve the T cell response.

November 11, 2014
E
National Harbor MD Fall Colors

SITC 2014 Cancer Immunotherapy Day 1

Reflections on Day 1 of the 2014 annual meeting of the Society for Immunotherapy of Cancer (SITC).

November 8, 2014
E
National Harbor Maryland

SITC 2014 Cancer Immunotherapy Workshop Review

Day 1 of the SITC annual meeting started with two workshops on immunotherapy and combination therapy

November 7, 2014
E
Washington DC in Fall

SITC 2014 Cancer Immunotherapy Annual Meeting Preview

This week sees the start of the 2014 annual meeting of the Society for Immunotherapy of Cancer (SITC) at National Harbor, MD. We’re excited to be attending this meeting for the first time.

November 4, 2014
E
ESMO 2014 Posters

Immuno-Oncology Gems in the ESMO Poster Halls

There was a lot going on in lung, melanoma, renal and colorectal cancer in terms of immunotherapy in Madrid.

November 3, 2014
E
ESMO Entrance Hall

Update on PD1 checkpoint inhibition in lung cancer

Merck announced their Breakthrough therapy designation for Keytruda in lung cancer this morning. What did we learn from the updated data for checkpoint inhibitors in NSCLC at ESMO that was different from ASCO?

October 27, 2014
E
ESMO 2014 Audience

New therapies are emerging for the treatment of advanced stomach cancer

Checkpoint inhibitors are looking very promising in advanced gastric cancer

October 23, 2014
E
ESMO 2014 Bladder Cancer

Breathing New Life into Bladder Cancer Treatment

At ESMO 2014, phase 1 clinical trial data in bladder cancer was presented for Pembrolizumab (Merck) and MPDL3280A (Roche/Genentech).

October 22, 2014
E
Roche Media Briefing ESMO 2014

Potential of IDO as Immunotherapy Target

Genentech and NewLink announced a deal to license an IDO inhibitor. What's the impact of this on the IO pipeline?

October 20, 2014
E
ESMO 2014 E Posters

ESMO 2014 Cancer Congress Day 3 Live Blog

Day 3 of the live blog from the ESMO 2014 Cancer Congress in Madrid.

September 28, 2014
E
ESMO 2014 Congress Madrid

ESMO 2014 Live Blog Day 2 #ESMO14

Day 2 Live Blog with news and commentary on what's taking place at the ESMO Cancer Congress in Madrid

September 28, 2014
E
Roche Promise of Immunotherapy Quote

ESMO 2014 Cancer Congress Day 1 Live Blog

ESMO 2014 Cancer Congress data starts to roll out today - throughout the day we'll be updating the blog with initial impressions of data as it's presented.

September 27, 2014
E
Air France Concorde Paris CDG

ESMO 2014 Takes Off with Release of Oral Abstracts #ESMO14

Most of the abstracts for oral presentations at the forthcoming ESMO cancer congress in Madrid have just been released. This is a preview of some that caught my attention.

September 24, 2014
E
Do not feed the Pelicans

ESMO 2014 Scientific Symposia Preview

There are some interesting science symposia at #ESMO14 in both immunotherapy and targeted therapies. We review what the hot topics are here.

September 19, 2014
E
St Pancras International

ESMO 2014 Poster Preview

A review of the key poster and poster discussion abstracts on immunotherapy and targeted therapies at ESMO 2014

September 18, 2014
E
Tall Ship Pageant

ESMO 2014 Preview: Immuno-oncology

Update on what to watch out for in immunotherapy at ESMO 2014.

September 16, 2014
E
Antoni Ribas ASCO 2014 Melanoma

What impact will nivolumab & pembrolizumab have on advanced melanoma?

How will we decide which therapies to give patients with metastatic melanoma once the new immunotherapies are available?

July 23, 2014
E
Cellectis CSO CEO

Can Cellectis Revolutionize CAR-T cell immunotherapy?

Cellectis is a Paris based biotechnology company with a “blue ocean” strategy that, if successful, could revolutionize cancer immunotherapy.

July 7, 2014
E
Kite Pharma Banner

Kite Pharma Challenges and Opportunities Post-IPO $KITE

After it's successful IPO, what are some of the challenges and opportunities facing Kite Pharma and their CAR-T cell immunotherapy?

June 23, 2014
E
ASCO 2014 Crowds

AstraZeneca MEDI4736 shows Immuno-Oncology promise at ASCO 2014

AstraZeneca showed impressive data at ASCO 2014 for MEDI4736, a new anti PD-L1 immunotherapy.

June 19, 2014
E
Chicago Board of Trade Building

Making a difference in advanced bladder cancer

There have been no new therapies in urothelial bladder cancer for 30 years - until now...

June 17, 2014
E
Chicago Art Institute

ASCO 2014 Nivolumab vs Pembrolizumab in Metastatic Melanoma

PD-1 antibodies nivolumab and pembrolizumab show considerable promise in metastatic melanoma. At ASCO 2014 we learnt more about how they compare against each other and their potential as a backbone for combinations.

June 16, 2014
E
ASCO 2014 Chicago the Bean

Combination strategies for nivolumab in Renal Cell Carcinoma

What does the ASCO 2014 data show when you combine checkpoint inhibitors nivolumab and ipilimumab?

June 13, 2014
E
T cell immunotherapy

6 important things I learned from AACR 2014 on immuno-oncology

Insights on checkpoint inhibitors, co-stimulants, CAR T cell therapy and bispecific antibody TCRs

May 2, 2014
E
AACR San Diego

New directions in immuno-oncology in biomarkers and combinations

Update on emerging potential immuno-oncology biomarkers and combinations from AACR

April 30, 2014
E
MSKCC Trial Suspensions

The real story behind Juno’s CAR T cell therapy suspensions

This weekend at AACR a controversy emerged on the safety of Juno's CAR T cell therapy.

April 6, 2014
E
Screenshot 2014-04-02 13.29.39

Innate immunotherapy – is it ready for prime time in cancer research?

A review of innate immunotherapies including CD47, KIR, MICA and anti-glucan data at AACR in San Diego.

April 2, 2014
E
Source: James Kochendefer, NCI

Will CAR T cells give new therapies for NHL and CLL a run for their money?

Much has been written about CAR T cells in B cell leukemias, but what about B cell lymphomas? Kite and the NCI had the honour of being the first to present data from ASH on their therapy in refractory DLBCL lymphomas

March 6, 2014
E
Anti-CTLA-4 ipilimumab

Update on immuno-oncology and biomarkers of response

ASCO GU saw an update on the ipilimumab study in post chemotherapy CRPC. New biomarker data published this week in melanoma may be potentially useful in prostate and other tumour types.

February 5, 2014
E
Screenshot 2014-02-04 15.14.55

ASCO GU 2014 Optimal targeting of anti PD-1 and PD-L1 therapies in renal cancer

Update on progress with anti-PD1 and PD-L1 immunotherapies in renal cell cancer. Where is the field going in this space?

February 4, 2014
E
Source: Roche

Update on anti-PD-L1 cancer immunotherapy

Roche Genentech are developing their anti-PD-L1 as both monotherapy and also in combination with targeted therapies in lung, melanoma, renal and colon cancers. How is the early development progressing?

January 22, 2014
E
Title Slide ASCO GI Keynote

ASCO GI Keynote: The future of Immunotherapy is Combinations

“We are at beginning of a REVOLUTION in immunotherapy,” said Elizabeth M. Jaffee, MD at the start of American Society of Clinical Oncology GastroIntestinal (ASCO GI) symposium keynote lecture on Immunologic Treatments for GI Cancers.

January 21, 2014
E
CAR T Cells

ASH 2013 Stunning ALL data with Novartis CTL019 CAR Therapy

UPenn and CHOP are using genetically modified chimeric antigen receptor (CAR) T cells to treat patients with B cell cancers such as ALL, B cell NHL, CLL and other B cell malignancies. At ASH, the impressive data from adult and pediatric ALL was presented. This post includes insights on this approach and an interview with Dr Stephan Grupp on the pediatric data.

January 9, 2014
E
Screen Shot 2014-01-07 at 11.22.26 AM

New Immunotherapy data at IASLC Lung Cancer Meeting

Immunotherapy continues to be a hot topic in oncology with anti-PD-1 and other new approaches being discussed at the AACR-IASLC meeting in San Diego

January 7, 2014
E
St Jude Penn Legal Case Citation

Juno Therapeutics takes on Penn in dispute over St Jude Chimeric Antigen Receptor Patent

Start-up Juno Therapeutics is now in control of a legal dispute between St Jude Children’s Hospital and the University of Pennsylvania over chimeric antigen receptor (CAR) T cells intellectual property that contributed to the development of CTL019 licensed by Penn to Novartis. Penn are seeking to invalidate a St Jude patent that if upheld, CTL019 may infringe.

January 6, 2014
E
Renier Brentjens ASH 2013 Disclosure

Juno Therapeutics takes on Novartis and seeks to revolutionize the treatment of blood cancers – an interview with Renier Brentjens

Juno Therapeutics is a start-up company with a mission to revolutionize the treatment of blood cancers through the use of chimeric antigen receptor (CAR) modified T cell therapy. The company recently launched with $120 million of series A funding. One of the scientific founders is Renier Brentjens MD, PhD, the Director of Cell Therapeutics at the Memorial Sloan-Kettering Cancer Center in NYC. He kindly gave an interview while at the ASH annual meeting in New Orleans.

December 13, 2013
E
KIR Occupancy by IPH2101

Will anti-KIR immunotherapy make an impact in hematologic malignancies?

Immuno-oncology is a hot topic at the moment and many new targets are emerging that may be useful in combination. This post discusses Innate Pharma's anti-KIR program in hematologic malignancies.

December 12, 2013
E
Brentjens CART Slide

ASH 2013 Preview: will new Seattle startup Juno Therapeutics push Novartis and U Penn in CART?

Chimeric Antigen Receptor T cell technology (CART) is an exciting new area, especially in hematologic malignancies. With the formation of a new start-up in Seattle, Juno Therapeutics, things just got very interesting...

December 4, 2013
E
Fall Colors Boston

New insights on checkpoint inhibitors and CART in CLL and solid tumors

An update on checkpoint inhibitors and CART from the AACR-NCI-EORTC Molecular Targets meeting - a lot of exciting possibilities are emerging!

October 25, 2013
E
IMG_8574

ECCO Day 3: Update on alectinib, PD-L1, PI3K and MEK

Update on ALK (alectinib), PD-L1 (MEDI4736), PI3K (GDC-0980 and BKM120) and MEK (trametinib) inhibitors in solid tumours

September 30, 2013
E
ECCO 2013 Conference Amsterdam

A top line look at the PD-1 and PD-L1 abstracts at ECCO 2013

A quick review of the check point immunotherapy abstracts from #ECC2013 in Amsterdam.

September 19, 2013
E
With permission from Dr Wolchok

How new approaches in targeted immunotherapy with anti-PD-1 and PD-L1 may change cancer research

Overview of anti-PD-1 and PD-L1 immunotherapies plus ASCO 2013 data in melanoma and lung cancer.

September 18, 2013
E
ASH 2012 Ernest Beutler Lecture

ASH 2012: CTL019 chimeric antigen receptor technology emerging as a new leukemia treatment

For many attendees, the most exciting news at the 2012 annual meeting of the American Society of Hematology (ASH) held last December in Atlanta was the prospect of personalized T cell therapy for the treatment of patients with B cell cancers such as chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL).

January 15, 2013